Stock Analiz

Atara Biotherapeutics, Inc. ATRA

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026

$7.70Market cap $78M
Open the interactive analysis →

Atara Biotherapeutics, Inc. (ATRA) is a healthcare company listed in the US with a market value of about $78M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$15M, a net margin of -368.6%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -113%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Atara Biotherapeutics

Atara Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $64M in 2022 to $121M in 2025, growth of about 23.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 212% over three years (dilution for shareholders). It spends 31% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • Interest covered more than 5 times

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S19.8
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-64.9%
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)-6.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-904.8%
ROIC (5-yr avg.)-113.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4M$121M$129M$9M$64M——————
Net income-$15M$33M-$85M-$276M-$228M-$340M-$307M-$291M-$231M-$119M-$79M
Free cash flow—-$51M-$69M-$194M-$275M-$231M-$185M-$241M-$216M-$108M-$63M
EPS (diluted)$-1.12$2.57$-11.41$-65.19$-56.01$-90.76$-103.76$-141.77$-131.76$-100.01$-68.76
Net margin-368.6%27.1%-66.2%-3220.9%-359.1%——————
ROIC———-139.6%-112.2%-87.4%-51.2%-76.3%-66.9%-68.3%-25.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Atara Biotherapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Atara Biotherapeutics pay a dividend?

Not currently.

Is Atara Biotherapeutics a good stock to buy?

We do not give buy or sell advice. Atara Biotherapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.